An Omicron-specific booster could be ready by August, the CEO of U.S. biotech firm Moderna told Reuters, but the firm is still gathering clinical data to determine whether that vaccine would offer better protection than a new dose of the existing jab.
Although the COVID-19 pandemic has hit companies unevenly, some biopharma firms that have produced new drugs or vaccines against the disease have shown big spikes in drug sales. BioSpace reviewed five companies that produced non-vaccine treatments for COVID-19.
Johnson & Johnson during late 2021 quietly shut down the only plant making usable batches of the company’s COVID-19 vaccine, the New York Times reported, citing people familiar with the decision.
Regeneron Pharmaceuticals Inc. on Feb. 4 reported fourth-quarter 2021 revenue that beat analysts’ estimates, boosted by demand for the blockbuster drugs Dupixent and Eylea, coupled with higher sales of the company’s COVID-19 therapy.
The U.S. antitrust regulator asked Biogen Inc. to present documents related to the approval and marketing of the company’s Alzheimer’s disease treatment, the drugmaker disclosed in a filing.
Pfizer Inc. on Nov. 2 said the company expected 2021 sales of the Covid-19 vaccine developed with German partner BioNTech SE would reach $36 billion and forecast another $29 billion from the shot in 2022, topping analyst estimates for both years.
Second-quarter 2021 sales of AstraZeneca’s Covid-19 vaccine more than tripled to $894 million from the first quarter, but the drugmaker on July 29 again delayed the U.S. application for approval as the company gathers more data for submissions.
Novartis reported second-quarter 2021 financials with net sales growing 15 percent to $12.96 billion. The company also reported on its Covid-19 vaccine production with CureVac and some pipeline updates.
One year after AbbVie’s $63 billion purchase of Allergan, the company is reportedly lining up the sale of a portfolio of women’s drugs and health care products valued at $5 billion.
Basel-based Lonza AG is moving to sell the company’s Lonza Specialty Ingredients division to private equity firms Bain Capital and Cinven for CHF 4.2 billion ($4.7 billion), completing a planned pivot to focus on Lonza Pharma, Biotech & Nutrition business.
